Morgan Stanley is out with its latest iron ore price outlook in which the firm’s strategists said they expect a return of more sustained upside and are targeting $120/t in Q3. They said that ...

Highlights,Analysts maintain strong interest with multiple buy ratings and a consensus price target of $89.10 for Disc Medicine (NASDAQ:IRON).,Insider trading reveals strategic selling and reshaping ...

Morgan Stanley analyst Vikram Purohit assumed coverage of Disc Medicine (IRON) with an Overweight rating and $85 price target The potentially ...